Literature DB >> 17964789

Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study.

Kamalesh Das1, Gouranga Prasad Mondal, Mousumi Banerjee, Bansi Badan Mukherjee, Om Prakash Singh.   

Abstract

Neurocysticercosis is a common cause of acquired seizure disorder in developing countries, including India. The role of antiparasitic (albendazole) therapy for seizure control and resolution of lesions is still controversial due to a lack of adequately controlled studies. The objective of the present study was to evaluate the role of albendazole therapy for neurocysticercosis patients with two or more lesions to achieve seizure-free status and resolution of lesions. This was a randomised controlled study in which patients suffering from neurocysticercosis were prospectively followed up for more than 5 years (from January 1997 to January 2005). Patients were divided into two groups: patients in group A (n=150) were treated with a combination of tapered doses of dexamethasone and albendazole, plus antiepileptic drugs; patients in group B (n=150) were treated with antiepileptic drugs plus a placebo control. Patients were followed up every month for the first 6 months and then at 3-month intervals thereafter up to 5 years. Variables of interest were (i) recurrence of seizures; (ii) encephalopathy (headache/vomiting/altered sensorium); (iii) need for subsequent hospital admission; (iv) death; (v) resolution of lesions on follow-up CT. During the first 6 months and at intervals thereafter, increased seizure frequency and hospital readmissions, and increased incidence of encephalopathy were observed in group A (p=0.01), and two patients in this group died with intractable seizures and encephalopathy. A greater proportion of lesions completely resolved in group B (p=0.05), whereas a greater proportion of lesions calcified in group A (p=0.05). Albendazole plus antiepileptic drugs did not have greater beneficial effects than antiepileptic drugs alone, but may have an adverse effect with respect to seizure control, encephalopathy, recurrent hospital admissions, calcification of lesions and cost of treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964789     DOI: 10.1016/j.jocn.2006.09.004

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  16 in total

Review 1.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

2.  The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.

Authors:  Kriti Thapa; Matthew L Romo; Arturo Carpio; Denise Leslie; Howard Andrews; W Allen Hauser; Elizabeth A Kelvin
Journal:  Trans R Soc Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.184

Review 3.  Anthelmintics for people with neurocysticercosis.

Authors:  Katharine Abba; Sridharan Ramaratnam; Lakshmi Narasimhan Ranganathan
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

4.  Neurocysticercosis.

Authors:  Pratibha Singhi
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

5.  Epilepsy in the developing world.

Authors:  Arturo Carpio; W Allen Hauser
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

Review 6.  Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management.

Authors:  Andrea Sylvia Winkler
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

Review 7.  Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis.

Authors:  Willem M Otte; Monika Singla; Josemir W Sander; Gagandeep Singh
Journal:  Neurology       Date:  2012-12-26       Impact factor: 9.910

8.  Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Ruth Ann Baird; Sam Wiebe; Joseph R Zunt; John J Halperin; Gary Gronseth; Karen L Roos
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

Review 9.  Epilepsy and neurocysticercosis in sub-Saharan Africa.

Authors:  Andrea Sylvia Winkler; Arve Lee Willingham; Chummy Sikalizyo Sikasunge; Erich Schmutzhard
Journal:  Wien Klin Wochenschr       Date:  2009-10       Impact factor: 1.704

Review 10.  Neurocysticercosis in children.

Authors:  Pratibha Singhi; Sunit Singhi
Journal:  Indian J Pediatr       Date:  2009-05-24       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.